The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment

Author(s): Hannelore Denys, Geert Braems, Kathleen Lambein, Patrick Pauwels, An Hendrix, Astrid De Boeck, Veronique Mathieu, Marc Bracke, Olivier De Wever

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 12 , 2009

Become EABM
Become Reviewer
Call for Editor


Emerging evidence points towards a key role of the extracellular matrix (ECM) during tumor progression and therapy resistance. Paradoxically, in todays routine of cancer management the ECM is not taken into account. It is the aim of the present review to broaden our understanding of the mechanisms of therapy resistance, taking the ECM as a presumptive central regulator. The stromal ecosystem drives the accumulation of ECM at the invasion front. Therefore, we address the question whether the detection of ECM signatures in histopathology and biofluids may help predicting therapy resistance and determining the prognosis of cancer. Since the ECM is an attractive target for tumor therapy, current therapeutic strategies in preclinical or clinical development will be discussed.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [1373 - 1384]
Pages: 12
DOI: 10.2174/138161209787846711
Price: $65

Article Metrics

PDF: 17